XUNFEIHEALTH(02506.HK): 2026 Interim Report - Profit Attributable to Shareholders stood at loss of CNY 59.3 million, loss narrowed by 19.95% YoY

NewTimeSpace News: August 18, 2026, XUNFEIHEALTH(02506.HK) released its Interim Report for the period ended December 31, 2026, Total Revenue stood at CNY 446.12 million, increased by 49.43% YoY; Net Profit stood at loss of CNY 48.1 million, loss narrowed by 41.54% YoY; Profit Attributable to Shareholders stood at loss of CNY 59.3 million, loss narrowed by 19.95% YoY; Basic Earnings Per Share (EPS) stood at loss of CNY 0.49.

In terms of profitability, XUNFEIHEALTH Gross Profit changed from CNY 153.87 million in the same period last year to CNY 236.11 million in the current period, increased by CNY 82.24 million; gross profit margin changed from 51.54% in the same period last year to 52.93% in the current period, increased by 1.39 percentage points; net profit changed from loss of CNY 82.28 million in the same period last year to loss of CNY 48.1 million in the current period, increased by CNY 34.18 million; net profit margin changed from -27.56% in the same period last year to -10.78% in the current period, increased by 16.78 percentage points.

In terms of earnings quality, XUNFEIHEALTH Operating Profit changed from loss of CNY 95.32 million in the same period last year to loss of CNY 57.63 million in the current period, increased by CNY 37.69 million; Operating Profit Margin changed from -31.93% in the same period last year to -12.92% in the current period, increased by 19.01 percentage points.

In terms of financial soundness, XUNFEIHEALTH Debt-to-Asset Ratio changed from 60.36% in the same period last year to 62.22% in the current period, increased by 1.86 percentage points; Total Equity changed from CNY 920.665 million in the same period last year to CNY 911.917 million in the current period, decreased by CNY 8.75 million; Current Liabilities changed from CNY 1.16 billion in the same period last year to CNY 1.4 billion in the current period, increased by CNY 241.09 million; Quick Ratio changed from 1.49 in the same period last year to 1.13 in the current period, decreased by 0.36 percentage points.

In terms of R&D investment focus, XUNFEIHEALTH R&D Expenses changed from CNY 114.51 million in the same period last year to CNY 151.33 million in the current period, increased by CNY 36.82 million; R&D to Total Revenue Ratio changed from 38.35% in the same period last year to 33.92% in the current period, decreased by 4.43 percentage points.

By the close of trading on August 18, 2026, XUNFEIHEALTH(02506) saw a loss of 0.63% in its share price, closing at HKD 63.35. The full-day turnover stood at HKD 1.57 million, with the latest market capitalization at HKD 4.9 billion.

NewTimeSpace Disclaimer:All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.